

Independent Evaluation of Four SARS-CoV-2 Antigen Rapid Tests Against qRT-PCR in Niger

Fatimata Hassane

Moussa Issa

Issifi Kollo Abdoukader

Wilfried Hounkanrin

Hadiza Ousmane

Bintou Kiari Kairo

Balki Aoula

Santou Mamadou

Centre for Medical and Health Research (CERMES), Niamey, Niger

Hama Hamidou Issa

Niamey National Hospital, Niamey, Niger

Bassira Issaka

Centre for Medical and Health Research (CERMES), Niamey, Niger

Emeline Capo Chichi

Gamkalle Clinic, Niamey, Niger

Ronan Jambou

Adamou Lagare

Centre for Medical and Health Research (CERMES), Niamey, Niger

[Doi:10.19044/esj.2026.v22n30p65](https://doi.org/10.19044/esj.2026.v22n30p65)

Submitted: 17 July 2026

Accepted: 20 October 2026

Published: 31 October 2026

Copyright 2026 Author(s)

Under Creative Commons CC-BY 4.0

OPEN ACCESS

Cite As:

Hassane, F., Issa, M., Abdoukader, I. K., Hounkanrin, W., Ousmane, H., Kairo, B. K., Aoula, B., Mamadou, S., Issa, H. H., Issaka, B., Chichi, E. C., Jambou, R., & Lagare, A. (2026). *Independent Evaluation of Four SARS-CoV-2 Antigen Rapid Tests Against qRT-PCR in Niger*. European Scientific Journal, ESJ, 22 (30), 65. <https://doi.org/10.19044/esj.2026.v22n30p65>

Abstract

Reliable, decentralized SARS-CoV-2 testing was a major challenge during the COVID-19 pandemic, particularly in low- and middle-income countries with limited molecular diagnostic capacity. We independently evaluated four commercial antigen rapid diagnostic tests (Ag-RDTs), including one manufactured in Africa, under routine field conditions in Niger. Between July 2021 and September 2023, four prospective evaluations were

conducted among symptomatic patients presenting within seven days of symptom onset at two health facilities in Niamey. The STANDARD Q nasopharyngeal, Panbio nasopharyngeal, Panbio nasal, and SAYTU nasal Ag-RDTs were compared with qRT-PCR as the reference standard. Overall, 956 patients were enrolled, including 422 (44.1%) qRT-PCR-positive cases. Sensitivity ranged from 75.0% to 85.7%, with the highest performance observed for the Panbio nasopharyngeal test (85.7%), followed by the SAYTU nasal test (80.1%), whereas specificity exceeded 95% for all assays. Sensitivity increased in specimens with high viral RNA concentration. Only the Panbio nasopharyngeal test met the World Health Organization performance criteria (sensitivity $\geq 80\%$ and specificity $\geq 97\%$). Nevertheless, the other three Ag-RDTs, including the Africa-manufactured SAYTU assay, may support screening in settings with limited molecular testing capacity, provided that negative results in symptomatic patients are confirmed by qRT-PCR.

Keywords: COVID-19 ; SARS-CoV-2 ; Rapid diagnostic test ; Sensitivity ; Specificity ; Niger

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic (Corman et al., 2020; Valencia, 2020). The virus is transmitted mainly by the respiratory route and causes a spectrum of disease ranging from asymptomatic infection to severe illness (Cucinotta & Vanelli, 2020; Rothan & Byrareddy, 2020). By 18 September 2022, more than 609 million confirmed cases and over 6.5 million deaths had been reported worldwide (World Health Organization, 2022). Testing suspected cases early in the course of illness is one of the most important measures for limiting household and community transmission (Ristic et al., 2021).

Real-time reverse-transcription polymerase chain reaction (qRT-PCR) remains the reference method for confirming SARS-CoV-2 infection because of its high accuracy, but it is laboratory-intensive and slow to return results (Corman et al., 2020; Sule & Oluwayelu, 2020; Younes et al., 2020). Antigen rapid diagnostic tests (Ag-RDTs) were developed to address these constraints, enabling point-of-care testing in decentralised and remote settings (Safiabadi Tali et al., 2021; Yamayoshi et al., 2020). Most Ag-RDTs use nasopharyngeal swabs, which require trained staff and personal protective equipment (Lindner et al., 2021); tests using less invasive, self-collectable nasal specimens are now available and improve patient acceptability (Agulló et al., 2021; Patriquin et al., 2022). More than a thousand commercial SARS-CoV-2 Ag-RDTs exist, with widely varying sensitivity and specificity (Xu et al., 2022). The World

Health Organization (WHO), in agreement with the European Centre for Disease Prevention and Control, has set minimum performance requirements of $\geq 80\%$ sensitivity and $\geq 97\%$ specificity for such assays (Al-Alawi et al., 2021).

Because Ag-RDT performance depends on the population tested, the circulating variants, the sampling method and operator conditions, in-country evaluation is recommended before a test is adopted into national policy. We therefore conducted four independent prospective evaluations of four SARS-CoV-2 Ag-RDTs against qRT-PCR among symptomatic patients in Niger. One of these tests, the SAYTU nasal assay (SAY-Na), is manufactured in Senegal and, to our knowledge, had not previously been independently evaluated; the others are used widely elsewhere but had not been assessed in the Niger context.

We aim here to generate locally relevant performance data to inform the national COVID-19 diagnostic algorithm during the pandemic.

Methods

Ethical considerations:

The ethical agreement for this research was obtained from the Comité National d'Ethique pour la Recherche en Santé (CNERS) by decision reference N°063/2021/CNERS. Written informed consent was obtained from each enrolled patient or legal guardian before sampling.

Study design and settings

We conducted four independent, prospective, hospital-based diagnostic-accuracy evaluations between July 2021 and September 2023, including: the STANDARD Q COVID-19 Ag nasopharyngeal test (STQ-Np; SD Biosensor Inc., Republic of Korea) from July to October 2021, the Panbio COVID-19 Ag Rapid Test Device nasopharyngeal (PANB-Np) and nasal (PANB-Na) formats (Abbott Diagnostics GmbH, Jena, Germany) from February to September 2022 and the SAYTU COVID-19 Ag nasal test (SAY-Na; DIATROPIX, Institut Pasteur de Dakar, with support from FIND and Unitaïd) from April to September 2023. All kits were donated to the Ministry of Public Health by international and regional partners, including the World Health Organization, the West African Health Organization, Africa CDC and non-governmental organisations. The evaluations were conducted at the Hôpital National de Niamey and the Clinique Gamkalle, both involved in COVID-19 case management in Niamey, Niger. All laboratory tests were performed at the Centre de Recherche Médicale et Sanitaire (CERMES), the national COVID-19 reference laboratory. The study is reported in line with the STARD 2015 guidance for diagnostic-accuracy studies.

Study population and sampling

Participants were enrolled using non-probability sampling to the prevalence of COVID-19 in Niamey during each study period. We included symptomatic patients of any age or sex with symptom onset ≤ 7 days who presented with one or more of the following: fever, cough, sore throat, rhinorrhoea, headache, fatigue or loss of smell. Clinical and demographic information was collected with a standardised questionnaire before sampling.

Index tests

Each Ag-RDT is a lateral-flow immunoassay for the qualitative detection of SARS-CoV-2 antigen in nasopharyngeal or nasal specimens (Patriquin et al., 2022). Depending on the test, a nasopharyngeal or nasal swab provided in the kit was used. Results were read at 15 min by a qualified clinician and recorded as positive or negative. Operators read the Ag-RDT before the qRT-PCR result was available but were not blinded to clinical presentation.

Reference standard

qRT-PCR served as the reference standard. RNA was extracted with the RADI PREP Swab and Stool DNA/RNA Kit (Ref S0003895) and amplified on a QuantStudio 5 Real-Time PCR System using the RADI COVID-19 Detection Kit (Ref RV008; KH Medical), targeting the S and RdRp genes. A cycle-threshold (Ct) value >38 was considered negative.

Statistical analysis

Data were recorded in Microsoft Excel 2013 and analysed in SPSS v26.0. Sensitivity was calculated as the proportion of qRT-PCR–positive specimens correctly identified by the Ag-RDT, and specificity as the proportion of qRT-PCR–negative specimens correctly identified. Ninety-five per cent confidence intervals were calculated using the Wilson score method. As an exploratory analysis, Ag-RDT sensitivity was stratified by qRT-PCR Ct value as a proxy for viral load.

Results

Participants

Across the four evaluations, 956 symptomatic patients (mean age 41.6 years; 593 [62.0%] male) were enrolled between July 2021 and September 2023. The most frequent symptoms were fever (75.6%) and cough (61.7%). Overall, 422 patients (44.1%) were positive by qRT-PCR. Because the four tests were evaluated in separate patient groups and at different times, results are reported separately for each test and are not compared directly (Table I).

Table 1: Diagnostic performance of four SARS-CoV-2 Ag-RDTs against qRT-PCR
(each test evaluated in a separate patient sample)

	PANB-Na (N = 212)	PANB-Np (N = 183)	STQ-Np (N = 151)	SAY-Na (N = 410)
qRT-PCR positive / negative, n (%)	59 (27.8) / 153 (72.2)	77 (42.1) / 106 (57.9)	75 (49.7) / 76 (50.3)	211 (51.5) / 199 (48.5)
Ag-RDT positive / negative, n (%)	52 (24.5) / 160 (75.5)	75 (41.0) / 108 (59.0)	56 (37.1) / 95 (62.9)	176 (42.9) / 234 (57.1)
Sensitivity, % (95% CI)	76.3 (63.4–86.4)	85.7 (75.9–92.6)	75.0 (63.4–84.0)	80.1 (74.1–85.3)
Specificity, % (95% CI)	95.4 (90.8–98.1)	98.1 (92.5–100)	100 (95.3–100)	96.5 (92.9–98.6)

STANDARD Q nasopharyngeal test (STQ-Np)

Of 151 patients tested, 75 (49.7%) were qRT-PCR positive and 56 (37.1%) were positive by STQ-Np. Sensitivity was 75.0% and specificity 100% (Table I). Among the 38 specimens with Ct ≤25, STQ-Np detected all positives, although this subgroup was small and the estimate imprecise. Concordance with qRT-PCR was 87.4%

Panbio nasal test (PANB-Na)

Of 212 patients tested, 59 (27.8%) were qRT-PCR positive and 52 (24.5%) were positive by PANB-Na. Sensitivity was 76.3% and specificity 95.4% ; concordance with qRT-PCR was 90.1% (Table I). In the high viral concentration RNA subgroup (Ct <20, n = 18), all PANB-Na results were positive, though the estimate is imprecise.

Panbio nasopharyngeal test (PANB-Np)

Of 183 patients tested, 77 (42.1%) were qRT-PCR positive and 75 (41.0%) were positive by PANB-Np. Sensitivity was 85.7% and specificity 98.1% ; concordance with qRT-PCR was 92.9% (Table I). Sensitivity was high at low Ct (Ct <20, n = 8) and at intermediate Ct (25<Ct<30, n = 32), though the strata were small.

SAYTU nasal test (SAY-Na)

Of 410 patients tested, 211 (51.5%) were qRT-PCR positive and 176 (42.9%) were positive by SAY-Na. Sensitivity was 80.1% and specificity 96.5%; concordance with qRT-PCR was 88.1% (Table I). Among high-viral-load specimens (Ct <20, n = 33), sensitivity was 97.0%. To our knowledge, this is the first independent field evaluation of this test. Sensitivity by Ct stratum for all four tests is shown in Figure 1.




Figure 1: Sensitivity of the four antigen tests by Ct stratum

Discussion

We evaluated four commercial SARS-CoV-2 Ag-RDTs from three manufacturers against qRT-PCR under routine conditions in Niger, with the explicit aim of generating locally relevant data to inform national testing policy. All four tests showed high specificity (>95%), but varied sensitivity, and only one test met the WHO performance criteria.

For STQ-Np, our sensitivity (75.0%) was higher than reports from Serbia (58.1%) and Oman (65.8%) (Al-Alawi et al., 2021; Ristic et al., 2021) but lower than those from Thailand (98.3%) and the Republic of Korea (89.2%) (Chaimayo et al., 2020; Kim et al., 2022); such differences are driven partly by the number and viral-load distribution of positive samples. Our estimate was close to the FIND independent evaluation of the STANDARD Q assay (sensitivity 78.6%, specificity 99.4%).

For PANB-Np, our sensitivity (85.7%) was slightly below the manufacturer's figure and a Spanish study (about 90%–91%) (Merino et al., 2021) but higher than other reports from Spain and France (47%–80%) (Albert et al., 2021; Farfour et al., 2021; Linares et al., 2020), where the inclusion of asymptomatic cases or retrospective samples may explain lower performance. For PANB-Na, our sensitivity (76.3%) was consistent with a Mozambican study (79.7%) (Sitoe et al., 2022); however, it exceeded reports from Spain, Canada and the Republic of Korea (44.7%–64.7%) (Agulló et al., 2021; Goodall et al., 2022; Oh et al., 2022). These differences are plausibly related to larger samples and longer symptom-onset windows.

SAY-Na, the only assay in this evaluation manufactured in Africa, performed broadly in line with the manufacturer's evaluation in Brazil

(sensitivity 89.2%, specificity 97.3%). Given the strategic importance of regional diagnostic manufacturing for pandemic preparedness in Africa, this first independent field evaluation is encouraging and supports further, larger assessment.

All the four tests performed best in high-viral-load specimens, consistent with the well-described association between antigen detection and viral load and the expected drop in sensitivity at Ct >30 (Dessalegn et al., 2022; Ristic et al., 2021; Scohy et al., 2020). Consistent with previous reports, nasal sampling offers a more acceptable, less invasive alternative to nasopharyngeal sampling and does not require specially trained staff (Dutta et al., 2022; Goodall et al., 2022; Père et al., 2020); some studies report modestly lower sensitivity with nasal swabs (Père et al., 2020; Wölfl-Duchek et al., 2022). Our data are compatible with this pattern, but because the nasal and nasopharyngeal Panbio formats were evaluated in different patients and at different times, we cannot make a direct within-study comparison between them.

Limitations

This study presents a number of limitations that warrant discussion. First, each test was assessed in a different group of patients and during a different phase of the pandemic, so the four estimates are not directly comparable and should not be read as a ranking. Second, the evaluations spanned from July 2021 to September 2023, during which several SARS-CoV-2 variants circulated. For instance, variant-related differences in antigen expression may have influenced detectability, and variant data were not available for individual specimens. Third, some subgroup analyses, including sensitivity by Ct stratum, were based on small numbers of samples, mainly explained by the low COVID-19 prevalence in Niger. Although the study included symptomatic patients whose symptoms had started ≤ 7 days before testing, the sensitivity of the Ag-RDTs was not analyzed according to symptom duration (e.g., 0–3 days versus 4–7 days). The absence of an analysis stratified by time since symptom onset represents an additional limitation, as Ag-RDT performance may vary depending on the duration of symptoms.

Conclusion

Timely detection of SARS-CoV-2 is essential for case management and outbreak control. All four antigen rapid diagnostic tests (Ag-RDTs) showed high specificity, but only PANB-Np met the WHO minimum performance criteria (sensitivity $\geq 80\%$ and specificity $\geq 97\%$). The other tests, including SAY-Na, showed appreciable sensitivity and may be useful for rapid screening where molecular diagnostic capacity is limited. However, the performance of SAY-Na cannot be directly compared with that of the imported

nasal test because of differences in the populations and periods evaluated. Further independent multicentre evaluations are needed before considering wider use of these tests.

Acknowledgements

The authors thank all patients who consented to participate, and the clinicians at the Hôpital National de Niamey and the Clinique Gamkalle who contributed to the study.

Authors' contributions

A.L., R.J., F.H. and M.I. conceived and designed the study. F.H., M.I, I.K.A., O.H., W.H., B.K.K., H.H.I., B.A., B.I., E.C.C. collected and analysed the data. F.H., M.I, I.K.A. and A.L. drafted the manuscript. A.L., S.M., R.J., M.I., E.C.C. and W.H. critically revised it. All authors read and approved the final manuscript.

Conflict of Interest: The authors reported no conflict of interest.

Data Availability: All data are included in the content of the paper.

Funding Statement: This study was funded in part by the French Ministry for Europe and Foreign Affairs through the project “Recherche Pasteurienne Internationale en Réponse au Coronavirus en Afrique” (REPAIR), which supported case enrolment and sample transport to CERMES. Test kits were provided by the Ministry of Public Health acquired through partner donations.

Declaration for Human Participants: This study has been approved by Comité National d’Ethique pour la Recherche en Santé (CNERS) by decision reference N°063/2021/CNERS and the principles of the Helsinki Declaration were followed.

References:

1. Agulló, V., Fernández-González, M., Ortiz de la Tabla, V., Gonzalo-Jiménez, N., García, J. A., Masiá, M., & Gutiérrez, F. (2021). Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. *Journal of Infection*, 82(5), 186–230. <https://doi.org/10.1016/j.jinf.2020.12.007>
2. Al-Alawi, S., Al-Hinai, H., Al-Kindi, N., Al-Rashidi, M., Al-Kindi, H., Al-Shukri, I., Al-Rashdi, A., Jose, S., & Al-Jardani, A. (2021). Evaluation of four rapid antigen tests for detection of SARS-CoV-2 virus. *Oman Medical Journal*, 36(5), Article e297.

3. Albert, E., Torres, I., Bueno, F., Huntley, D., Molla, E., Fernández-Fuentes, M. Á., Martínez, M., Poujois, S., Forqué, L., Valdivia, A., Solano de la Asunción, C., Ferrer, J., Colomina, J., & Navarro, D. (2021). Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. *Clinical Microbiology and Infection*, 27(3), 472.e7–472.e10.
4. Chaimayo, C., Kaewnaphan, B., Tanlieng, N., Athipanyasilp, N., Sirijatuphat, R., Chayakulkeeree, M., Angkasekwinai, N., Sutthent, R., Puangpunngam, N., Tharmviboonsri, T., Pongraweeewan, O., Chuthapisith, S., Sirivatanauksorn, Y., Kantakamalakul, W., & Horthongkham, N. (2020). Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. *Virology Journal*, 17(1), Article 177. <https://doi.org/10.1186/s12985-020-01452-5>
5. Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M. L., Mulders, D. G., Haagmans, B. L., van der Veer, B., van den Brink, S., Wijsman, L., Goderski, G., Romette, J.-L., Ellis, J., Zambon, M., ... Drosten, C. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*, 25(3). <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
6. Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic. *Acta Biomedica*, 91(1), 157–160. <https://doi.org/10.23750/abm.v91i1.9397>
7. Dessalegn, D., Tola, E. K., Tamiru, A., & Zerfu, B. (2022). Evaluation of the performance of Panbio COVID-19 antigen rapid diagnostic test for the detection of SARS-CoV-2 in suspected patients in Ethiopia. *SAGE Open Medicine*, 10. <https://doi.org/10.1177/20503121221110079>
8. Dutta, D., Naiyer, S., Mansuri, S., Soni, N., Singh, V., Bhat, K. H., Singh, N., Arora, G., & Mansuri, M. S. (2022). COVID-19 diagnosis: A comprehensive review of the RT-qPCR method for detection of SARS-CoV-2. *Diagnostics*, 12(6). <https://doi.org/10.3390/diagnostics12061503>
9. Faico-Filho, K. S., Ferreira Junior, F. E., Moreira, L. V. L., Lins, P. R. G., Justo, A. F. O., & Bellei, N. (2022). Evaluation of the Panbio COVID-19 Ag rapid test at an emergency room in a hospital in São Paulo, Brazil. *Brazilian Journal of Infectious Diseases*, 26(2). <https://doi.org/10.1016/j.bjid.2022.102349>
10. Farfour, E., Amiel, C., Jolly, E., Zia-Chahabi, S., Mazaux, L., Simonin, P., Berkane, I., Cornily, M., Pascreau, T., & SARS-CoV-, M (2021). The Panbio COVID-19 Ag rapid test: Which performances are for

- COVID-19 diagnosis? *Clinical Laboratory*, 67(11).
<https://doi.org/10.7754/Clin.Lab.2021.210304>
11. Goodall, B. L., LeBlanc, J. J., Hatchette, T. F., Barrett, L., & Patriquin, G. (2022). Investigating the sensitivity of nasal or throat swabs: Combination of both swabs increases the sensitivity of SARS-CoV-2 rapid antigen tests. *Microbiology Spectrum*, 10(4).
<https://doi.org/10.1128/spectrum.00217-22>
 12. Kim, H. W., Park, M., & Lee, J. H. (2022). Clinical evaluation of the rapid STANDARD Q COVID-19 Ag test for the screening of SARS-CoV-2. *Annals of Laboratory Medicine*, 42(1), 100–104.
<https://doi.org/10.3343/alm.2022.42.1.100>
 13. Linares, M., Pérez-Tanoira, R., Carrero, A., . (2020). Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. *Journal of Clinical Virology*, 133.
<https://doi.org/10.1016/j.jcv.2020.104659>
 14. Lindner, A. K., Nikolai, O., Rohardt, C., S., Hülso, C., Bölke, A., Gertler, M., Krüger, L. J., Gaeddert, M., Tobian, F., Lainati, F., Seybold, J., Jones, T. C., Hofmann, J., Sacks, J. A., Mockenhaupt, F. P., & Denkinger, C. M. (2021). Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab. *European Respiratory Journal*, 57(5).
<https://doi.org/10.1183/13993003.04430-2020>
 15. Merino, P., Guinea, J., Muñoz-Gallego, I., González-Donapetry, P., Galán, J. C., Antona, N., Cilla, G., Hernáez-Crespo, S., Díaz-de Tuesta, J. L., Gual-de Torrella, A., González-Romo, F., Escribano, P., Sánchez-Castellano, M. Á., Sota-Busselo, M., Delgado-Iribarren, A., García, J., Cantón, R., Muñoz, P., Folgueira, M. D., ... Oteo-Iglesias, J. (2021). Multicenter evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. *Clinical Microbiology and Infection*.
<https://doi.org/10.1016/j.cmi.2021.02.001>
 16. Oh, S. M., Lee, J. S., Jo, H. J., Kim, D., Park, D., Hwang, Y. H., Choi, Y., Lee, C. M., Lee, S., Chang, E., Lee, E., Kim, T. S., Seong, M.-W., Choe, P. G., & Kim, N. J. (2022). Clinical application of the Panbio COVID-19 Ag rapid test device and SSf-COVID19 kit for the detection of SARS-CoV-2 infection. *BMC Research Notes*, 15(1), Article 357. <https://doi.org/10.1186/s13104-022-06226-6>
 17. Patriquin, G., LeBlanc, J. J., Williams, C., Hatchette, T. F., Ross, J., Barrett, L., & Davidson, R.. (2022). Comparison between nasal and nasopharyngeal swabs for SARS-CoV-2 rapid antigen detection in an asymptomatic population. *Microbiology Spectrum*, 10(1), Article e0245521. <https://doi.org/10.1128/spectrum.02455-21>

18. Père, H., Podglajen, I., Wack, M., Flamarion, E., Mirault, T., Goudot, G., Hauw-Berlemont, C., Le, L., Caudron, E., Carrabin, S., Rodary, J., Ribeyre, T., Bélec, L., & Veyer, D. (2020). Nasal swab sampling for SARS-CoV-2: A convenient alternative in times of nasopharyngeal swab shortage. *Journal of Clinical Microbiology*, 58(6). <https://doi.org/10.1128/JCM.00721-20>
19. Ristic, M., Nikolic, N., Cabarkapa, V., Turkulov, V., & Petrovic, V. (2021). Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia. *PLOS ONE*, 16(2), Article e0247606. <https://doi.org/10.1371/journal.pone.0247606>
20. Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*, 109, Article 102433. <https://doi.org/10.1016/j.jaut.2020.102433>
21. Safiabadi Tali, S. H., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi-Anbuhi, S. (2021). Tools and techniques for SARS-CoV-2/COVID-19 detection. *Clinical Microbiology Reviews*, 34(3). <https://doi.org/10.1128/CMR.00228-20>
22. Scohy, A., Anantharajah, A., Bodeus, M., Kabamba-Mukadi, B., Verroken, A., & Rodriguez-Villalobos, H. (2020). Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *Journal of Clinical Virology*, 129, <https://doi.org/10.1016/j.jcv.2020.104455>
23. Singh, B., Datta, B., Ashish, A., & Dutta, G. (2021). A comprehensive review on current COVID-19 detection methods. *Sensors International*, 2, Article 100119. <https://doi.org/10.1016/j.sintl.2021.100119>
24. Siteo, N., Sambo, J., Mabunda, N., Nguenha, N., Chilaúle, J., Rafael, J., Macicame, A., Chelene, I., Mudenyanga, C., Sacks, J., Viegas, S., Loquiha, O., & Jani, I.. (2022). Clinical performance of self-collected nasal swabs and antigen rapid tests for SARS-CoV-2 detection in resource-poor settings. *Biomedicines*, 10(9). <https://doi.org/10.3390/biomedicines10092327>
25. Sule, W. F., & Oluwayelu, D. O. (2020). Real-time RT-PCR for COVID-19 diagnosis: Challenges and prospects. *Pan African Medical Journal*, 35(Suppl 2), Article 121. <https://doi.org/10.11604/pamj.suppl.2020.35.24258>
26. Valencia, D. N. (2020). Brief review on COVID-19: The 2020 pandemic caused by SARS-CoV-2. *Cureus*, 12(3), Article e7386. <https://doi.org/10.7759/cureus.7386>

27. Wölfl-Duchek, M., Bergmann, F., Jorda, A., Weber, M., Müller, M., Seitz, T., Zoufaly, A., Strassl, R., Zeitlinger, M., Herkner, H., Schnidar, H., Anderle, K., & Derhaschnig, U. (2022). Sensitivity and specificity of SARS-CoV-2 rapid antigen detection tests using oral, anterior nasal, and nasopharyngeal swabs: A diagnostic accuracy study. *Microbiology Spectrum*, 10(1), Article e0202921. <https://doi.org/10.1128/spectrum.02029-21>
28. World Health Organization. (2022). *Novel coronavirus (2019-nCoV) situation report*. Geneva: WHO; 2022.
29. Xu, J., Kerr, L., Jiang, Y., Suo, W., Zhang, L., Lao, T., Chen, Y., & Zhang, Y. (2022). Rapid antigen diagnostics as frontline testing in the COVID-19 pandemic. *Small Science*, 2(8). <https://doi.org/10.1002/smssc.202200009>
30. Yamayoshi, S., Sakai-Tagawa, Y., Koga, M., Akasaka, O., Nakachi, I., Koh, H., Maeda, K., Adachi, E., Saito, M., Nagai, H., Ikeuchi, K., Ogura, T., Baba, R., Fujita, K., Fukui, T., Ito, F., Hattori, S., Yamamoto, K., Nakamoto, T., ... Kawaoka, Y. (2020). Comparison of rapid antigen tests for COVID-19. *Viruses*, 12(12). <https://doi.org/10.3390/v12121420>
31. Younes, N., Al-Sadeq, D. W., Al-Jighefee, H., Younes, S., Al-Jamal, O., Daas, H. I., Yassine, Hadi. M., & Nasrallah, G. K. (2020). Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2. *Viruses*, 12(6). <https://doi.org/10.3390/v12060582>